Roman R Schimmer

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Acute Myeloid Leukemia

Replacement Therapy

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

EMBO molecular medicine

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Roman R Schimmer, Tabea Sutter, Adrian Bachofner, Elisabetta Ranieri, Ann-Kathrin Rodewald, Johanna A Kremer Hovinga, Nina Kimmich, Alice Trinchero, Jan-Dirk Studt
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab. British journal of haematology 204 (5) (2024)
Roman R Schimmer, Tabea Sutter, Adrian Bachofner, Elisabetta Ranieri, Ann-Kathrin Rodewald, Johanna A Kremer Hovinga, Nina Kimmich, Alice Trinchero, Jan-Dirk Studt
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab. British journal of haematology 204 (5) (2024)
Roman R Schimmer, Tabea Sutter, Adrian Bachofner, Elisabetta Ranieri, Ann-Kathrin Rodewald, Johanna A Kremer Hovinga, Nina Kimmich, Alice Trinchero, Jan-Dirk Studt
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab. British journal of haematology (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine 16 (3) (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine 16 (3) (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine 16 (3) (2024)
Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre Pa Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus Gabriel Manz, Steffen Boettcher
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO molecular medicine 16 (3) (2024)
Roman R Schimmer, Larisa V Kovtonyuk, Nancy Klemm, Jonas Fullin, Sebastian M Stolz, Jan Mueller, Francisco Caiado, Kari J Kurppa, Benjamin L Ebert, Markus G Manz, Steffen Boettcher
TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood advances 6 (11) (2022)